A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 157 participants.

Also called NCT05615363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 157 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05615363
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05615363. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-10 (actual); primary completion 2024-10-21 (actual). Results posted on 2025-10-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
Condition
Cardiac Edema (CHF)
Intervention (Drug)
OPC 131461 10mg group
Intervention (Drug)
OPC 131461 5mg group
Intervention (Drug)
OPC 131461 2mg group
Intervention (Drug)
OPC 131461 1mg group
Intervention (Drug)
Placebo
Lead sponsor
Otsuka Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05615363
Content hash
676cd81f0ee4b975a59f4dabc4f391b56fbe80fb43445552e4bdb3249c109abb